Event Details

As part of the Cambridge Biotech week, KPMG and One Nucleus are pleased to invite you to a luncheon where we will be sharing the latest developments of the biotech ecosystem in Hong Kong and the opportunities for early stage and mature biotech companies in the UK.


Over the past two years, over US$13 billion and a variety of policies were launched by the Hong Kong government to spur technology innovation in the City. Among those developments include the new public listing regime for pre-revenue biotech companies on the Hong Kong Exchange, two research clusters on healthcare and on artificial intelligence and robotics, and and the release of the Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area by China's central government. The Greater Bay Area, comprising nine cities in Guangdong's Pearl River Delta, as well as Hong Kong and Macau, will cooperate and invest significant resources to become a globally influential international innovation and technology hub.


Our discussion will be led by representatives from the Hong Kong Exchanges and Clearing (HKEx), and Hong Kong Science and Technology Park (HKSTP) - a public corporation entrusted by the Government of Hong Kong to spur innovation and advancements in the fields of Biomedical Technology, Electronics, Green Technology, Information and Communications Technology, Material and Precision Engineering.

Jun 27, 2019

12 PM - 2:30 PM

Add to Calendar

KPMG Cambridge Office
Botanic House
100 Hills Road

Cambridge, CB2 1AR, United Kingdom

Show on map

Agenda

  • 12 PM - 12:30 PMArrival and sandwich buffet
    12:30 PM - 12:35 PMOpening Address

    Irene N.Y. Chu

    Partner, Head of Life Sciences, Hong Kong at KPMG China

    Andrew Muncey

    CFO at Artios Pharma Limited

    12:35 PM - 12:50 PMHong Kong's Biotech ecosystem and the opportunities for UK biotech companies in the Greater Bay Area

    Simon Sze

    Associate Director of Hong Kong Science & Technology Parks Corporation

    12:50 PM - 1:05 PMHKEx's new Biotech chapter and funding opportunities in Hong Kong

    Michael Chan

    Senior Vice President, Head of International Issuer Services at Hong Kong Exchanges and Clearing Limited (HKEX)

    1:05 PM - 1:50 PMPanel Discussion: Hong Kong as a destination for Biotech advancements & capital raising

    Michael Chan

    Senior Vice President, Head of International Issuer Services at Hong Kong Exchanges and Clearing Limited (HKEX)

    Irene N.Y. Chu

    Partner, Head of Life Sciences, Hong Kong at KPMG China

    Simon Sze

    Associate Director of Hong Kong Science & Technology Parks Corporation

    Andrew Muncey

    CFO at Artios Pharma Limited

    1:50 PM - 2 PMQ&A
    2 PM - 2:30 PMNetworking

Speakers

  • Michael Chan (Senior Vice President, Head of International Issuer Services at Hong Kong Exchanges and Clearing Limited (HKEX))

    Michael Chan

    Senior Vice President, Head of International Issuer Services at Hong Kong Exchanges and Clearing Limited (HKEX)

    Read Bio
  • Irene N.Y. Chu (Partner, Head of Life Sciences, Hong Kong at KPMG China)

    Irene N.Y. Chu

    Partner, Head of Life Sciences, Hong Kong at KPMG China

    Read Bio
  • Andrew Muncey (CFO at Artios Pharma Limited)

    Andrew Muncey

    CFO at Artios Pharma Limited

    Read Bio
  • Simon Sze (Associate Director of Hong Kong Science & Technology Parks Corporation)

    Simon Sze

    Associate Director of Hong Kong Science & Technology Parks Corporation

    Read Bio
Menu